Although the U.S. stock market shook off worse than expected retail sales data, volatility hit other markets hard to end the week.

Precious metals were slammed on the retail sales data along with some signs of deflationary pressures in Friday's economic data. Technical levels were broken to the downside during the

Jefferies noted, “IMGN and partner Roche announced that Kadcyla (T-DM1) has been approved and priced at $9,800 per month. Kadcyla pricing is 33% higher than we

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to

Jefferies noted, “On its F2Q13 call, IMGN highlighted progress on its earlier stage, internally developed programs including 901, 854, and 529, all of which are

Procter & Gamble Co (NYSE: PG) is expected to report its Q2 earnings at $1.11 per share on revenue of $21.91 billion.

Oshkosh (NYSE: OSK) is

A Peek Into Global Markets European markets were lower today. The STOXX Europe

Figure 1.  Cancer Prevalence.

In our recent past, monoclonal antibodies (mAbs) were discussed in the context of a mid-tiered pharma, BIIB and smaller biotech, Immunogen (IMGN).  These companies will not be rehashed, but to re-emphasize that mAb and biologics are one of the hottest areas in in biotech.  Small molecules have are not the favorites for now (especially in cancer), and that is most likely due to early stage trials, lack of efficacy, or more likely – patent protection, as biologics/mAbs are harder to show equivolance….and thus have the potential to generate cash for years to come. 

(IMMU) based in New Jersey, is primarily focused on the development of mAb-based products for the targeted treatment of cancer, autoimmune and other diseases.  The company has a number of advanced mAbs that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents (think Inmunogen, but different ‘targets’).  The company has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action discussed below.  The company also owns a stake in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology.  This DNL technology can be used for making fusion proteins as well as a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based,…